Heart failure is a serious condition with a high morbidity and mortality. The patient enrolment and 1 year follow-up was finalized for all heart failure patients January 2021 in the Danish Ischemic Heart Failure phase II Trial (81 patients), in the International multi-centre SCIENCE Ischemic Heart Failure Phase II Trial (133 patients) and in the Non Ischemic Heart Failure phase I-II Trial (30 patients).
All safety and efficacy data will be ready for publication late 2021.
